hivandhepatitis.com

CROI 2013: MK-1439, a Novel HIV NNRTI, Shows Promise in Early Clinical Trials

A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated robust antiretroviral activity and good tolerability as monotherapy in a small clinical study, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Read more:

CROI 2013: Health Insurance Coverage Linked to HIV Viral Load Suppression [VIDEO]

Whether people with HIV have health insurance -- and the type of coverage they have -- influences the likelihood of viral suppression, according to a poster presentation Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Read more:

CROI 2013: Very Early Antiretroviral Treatment Limits the Size of HIV Reservoir

Very early antiretroviral treatment may limit the size of the HIV reservoir in adults and children, according to studies presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. Other research presented at the meeting suggests that too little is known about either the size or the cell types that constitute the HIV reservoir to be confident that early assessments will be a reliable guide to the potential for viral eradication.

Read more:

Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.

Conference highlights include experimental therapies for HIV and hepatitis C, HIV cure research, aging, HIV-related conditions and treatment complications, HIV treatment as prevention and PrEP,  and HIV/HBV and HIV/HCV coinfection.

Full listing by topic 

HIVandHepatitis.com CROI 2013 conference section

CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment

New antiretroviral drugs and treatment strategies are no longer the predominant focus of the annual Conference on Retroviruses and Opportunistic Infections (CROI), but this year's meeting included several presentations on refinements to HIV therapy that offer the prospect of greater efficacy -- especially for people with resistant virus --  fewer side effects, and more convenient administration.

Read more:

CROI 2013: Development of Small Molecules for HIV Eradication [VIDEO]

Research towards a cure for HIV is a key theme of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), taking place this week in Atlanta. One of the many approaches under study is the use of small molecules to bring resting HIV out of latency, in an effort to ultimately eradicate the virus from the body.

Read more: